Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and tolerability of INZ-701, an ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of
ABCC6 Deficiency (including Generalized Arterial Calcification of Infancy Type 2 [GACI-2] and
Pseudoxanthoma elasticum [PXE]).